We’re happy to report that the University of Texas is now starting a Phase II clinical trial of VG Life Sciences’ combination cancer therapy. VGLS holds Patent No. 9073985 covering the combination therapy used in this trial.

The Phase I clinical trial was conducted at the University of Texas Health Science Center at San Antonio. That trial involved patients with solid tumors and examined the safety and efficacy of hydroxychloroquine (HCQ) in combination with sorafenib (marketed as Nexavar®), co-developed by Bayer AG and Onyx Pharmaceuticals.

In Phase I, tumor reduction and stabilization was shown in a number of patients in the third and fourth cohorts, all of whom had higher doses of the combination therapy. The design of this clinical trial allowed us to conclude that these positive effects can be attributed to the combination therapy and not sorafenib alone.

Author VGLS     Tags combination cancer therapy, HCQ, Nexavar, tumor, tumor reduction, university of texas